Samrat Pharmachem Ltd (530125)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Samrat Pharmachem's revenue was ₹79.8 Cr (+5.4% year on year, +11.1% on the previous quarter), and net profit ₹0.9 Cr (against a loss a year earlier); the operating margin was 1.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹79.8 | +5.4% | +11.1% |
| Operating profit | ₹0.9 | +591.5% | from loss |
| Net profit | ₹0.9 | from loss | from loss |
| EPS (₹) | 2.84 | from loss | from loss |
| Operating margin | 1.1% | — | — |
📢 Recent Corporate Announcements
Samrat Pharmachem Limited has scheduled a meeting of its Board of Directors on Saturday, November 14, 2026. The board will meet inter alia to consider and approve the un-audited financial results for the quarter ended September 30, 2026. This is a routine regulatory intimation pursuant to Regulation 29(2) of SEBI LODR Regulations.
- Board meeting date fixed for Saturday, November 14, 2026
- Meeting time scheduled at 02:00 P.M. at Corporate Office in Mumbai
- Agenda: Approval of un-audited Ind-AS financial results for the quarter ended September 30, 2026
Samrat Pharmachem has submitted its Scrutinizer's Report and voting results for the 34th Annual General Meeting held on September 23, 2026. All four resolutions presented—including adoption of FY26 financial statements, re-appointment of director Megh Mehta, appointment of statutory auditors for 5 years (FY27 to FY31), and ratification of cost auditor remuneration—were approved. Each resolution secured 1,398,773 votes in favor (97.5589%) and 35,000 votes against (2.4411%). The company generated TTM revenues of Rs 294 Cr with a net loss of Rs 2 Cr.
- All 4 ordinary resolutions approved with 97.5589% votes in favor
- Total valid votes cast were 14,33,773 across remote e-voting and AGM e-voting
- Appointment of Statutory Auditors confirmed for a 5-year term from FY 2026-27 to FY 2030-31
- 35,000 votes (2.4411%) were cast against each resolution
Samrat Pharmachem Limited has scheduled its 34th Annual General Meeting (AGM) for Wednesday, September 23, 2026, at 1:00 PM IST via video conferencing. The company's Register of Members and Share Transfer books will remain closed from September 20, 2026, to September 22, 2026 (both days inclusive). The voting eligibility cut-off date for shareholders is fixed as Wednesday, September 16, 2026. Remote e-voting will be accessible from September 20, 2026 (9:00 AM IST) through September 22, 2026 (5:00 PM IST).
- 34th AGM scheduled for September 23, 2026 at 1:00 PM IST via VC/OAVM
- Share transfer books and register of members closed from September 20 to September 22, 2026
- Cut-off date for determining voting rights fixed as September 16, 2026
- Remote e-voting window runs from September 20 (9:00 AM IST) to September 22, 2026 (5:00 PM IST)
Samrat Pharmachem Limited has announced that its 34th Annual General Meeting (AGM) will be held on Wednesday, September 23, 2026, at 1:00 PM IST through Video Conferencing. The cut-off date to determine shareholder voting eligibility is Wednesday, September 16, 2026. The remote e-voting window is scheduled from September 20, 2026, to September 22, 2026, during which share transfer books will also remain closed.
- 34th AGM scheduled for Wednesday, September 23, 2026, at 1:00 PM IST via VC/OAVM
- Cut-off date for remote e-voting eligibility set as September 16, 2026
- Remote e-voting open from Sunday, September 20, 2026 (9:00 AM IST) to Tuesday, September 22, 2026 (5:00 PM IST)
- Register of Members and Share Transfer Books closed from September 20, 2026, to September 22, 2026
Samrat Pharmachem Limited has submitted its 34th Annual Report for FY 2025-26 along with the notice convening its 34th Annual General Meeting (AGM) on September 23, 2026, via Video Conferencing. Key agenda items include adoption of FY26 financial statements, re-appointment of Director Mr. Megh Mehta, and the appointment of M/s. Divyesh J Shah & Associates as Statutory Auditors for a 5-year term (FY 2026-27 to FY 2030-31). The remote e-voting window runs from September 20, 2026, to September 22, 2026.
- 34th Annual General Meeting scheduled for September 23, 2026 at 1:00 PM IST via Video Conferencing
- Remote e-voting period open from September 20, 2026 (9:00 AM IST) to September 22, 2026 (5:00 PM IST)
- Appointment of M/s. Divyesh J Shah & Associates as Statutory Auditors proposed for a 5-year tenure up to FY 2030-31
- Adoption of audited financial statements for FY26 (FY26 revenue of Rs 289.72 Cr and net loss of Rs 3.32 Cr)
Samrat Pharmachem reported a standalone revenue from operations of ₹79.76 crore for Q1 ended June 30, 2026, marking a 5.4% YoY increase and 11.1% QoQ growth. The company swung back into profitability with a net profit of ₹0.88 crore compared to a net loss of ₹0.23 crore in Q1 FY26 and a net loss of ₹2.04 crore in Q4 FY26. Profit before tax stood at ₹1.59 crore, recovering from a PBT loss of ₹1.87 crore in the preceding quarter. Diluted EPS for the quarter came in at ₹2.84 compared to ₹(0.74) YoY.
- Revenue from operations grew 5.43% YoY to ₹79.76 crore (₹7,976.10 lakhs) vs ₹75.65 crore in Q1 FY26
- Turned profitable with standalone PAT of ₹0.88 crore (₹87.60 lakhs) vs net loss of ₹0.23 crore YoY and ₹2.04 crore QoQ
- Profit before tax stood at ₹1.59 crore (₹158.53 lakhs) vs ₹0.21 crore in Q1 FY26
- Diluted EPS improved to ₹2.84 per share from ₹(0.74) in the prior-year period
Samrat Pharmachem has approved the appointment of M/s. Divyesh J Shah & Associates as the company's Statutory Auditors for a five-year period. The term commences from the conclusion of the 34th Annual General Meeting (AGM) and extends until the 39th AGM, pending shareholder approval. The firm, established in 1998, brings experience in BSE inspections and debt syndication. This move follows the recommendation of the Audit Committee and a Board meeting held on July 15, 2026.
- Appointment for a fixed term of 5 years starting from the 34th AGM
- Board approval finalized on July 15, 2026, during a 90-minute meeting
- Auditor firm Divyesh J Shah & Associates has been established since 1998
- The firm has prior experience with BSE for inspection of stock brokers regarding fraud detection
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
